News

The deal now includes shared antigen mRNA cancer vaccines including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine. Merck and Moderna will now jointly advance mRNA-5671 in human studies, and

Novartis firm Sandoz received a complete response letter (CRL) regarding the BLA for biosimilar rituximab and is planning to conduct further discussions with FDA to bring the medicine to

Delian Capital led the investment round with participation from existing and new investors including OnKure management. The investment will help the company aggressively accelerate its research and development

Merck executive board member and Merck healthcare CEO Belén Garijo said: "Our collaboration with SFJ illustrates Merck KGaA, Darmstadt, Germany's increasing focus on strategic partnering in order to

Janssen Biotech is one of the Janssen Pharmaceutical Companies owned by Johnson & Johnson. BeneVir is a portfolio company within HC2’s Pansend Life Sciences subsidiary. BeneVir is currently

This is the first of what the Company expects will be a series of product acquisitions designed to generate revenue and strengthen its financial position. Vivus CEO John

The collaboration utilises both companies’ drug discovery technologies, in particular C4XD’s Taxonomy3 novel target identification platform and ETX’s Network-driven Drug Discovery (NDD) capabilities. Teams from both companies will

The new indication approved by the US Food and Drug Administration (FDA) covers diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL. The immunocellular therapy has

The application seeks approval for KEYTRUDA in combination with pemetrexed (ALIMTA) and platinum chemotherapy (carboplatin or cisplatin) as a first-line treatment for patients with metastatic nonsquamous non-small cell